An initiative at a cancer center encouraged nurses to “Have a Seat” while performing some nursing care improved patient perceptions of the care they received.

A multi-institutional study led by Moffitt Cancer Center found that percutaneous hepatic perfusion using a melphalan hepatic delivery system may help patients with a rare eye cancer that has spread to ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

Benefits advisors need to stay proactive and help their clients leverage formulary design, clinical oversight, and ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with ...

“I am pleased to welcome Teresa to our Board of Directors,” said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. “She is a seasoned leader whose extensive operational and ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Net loss: US$88.0m (loss widened by 30% from FY 2023). US$1.41 loss per share. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to ...

Predictive Oncology Trading Up 0.9 % Shares of POAI opened at $1.12 on Tuesday. The firm’s fifty day simple moving average is $1.34 and its two-hundred day simple moving average is $1.00.

Analysts expect Mural Oncology to post earnings of ($1.98) per share for the quarter. Mural Oncology ( NASDAQ:MURA – Get Free Report ) last announced its earnings results on Tuesday, March 11th.